Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
Intensive chemotherapy is often associated with low platelet counts often requiring platelet
transfusions to maintain platelet counts. In previous clinical studies administration of
rhTPO has been demonstrated to increase platelet counts.